
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MITI-101
Therapeutic Area : Neurology
Study Phase : IND Enabling
Recipient : Wheeler Bio
Deal Size : Undisclosed
Deal Type : Agreement
Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement
Details : Wheeler Bio will provide integrated process development and cGMP drug substance manufacturing services via its ModularCMC™ platform to support the advancement of the MITI-101 program.
Product Name : MITI-101
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 17, 2025
Lead Product(s) : MITI-101
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Recipient : Wheeler Bio
Deal Size : Undisclosed
Deal Type : Agreement
